Prices for obesity medication .. Why do some drop and rise others?

A new category of weight loss medicine, known as the GLP-1, caused radical transformations for obese people, while billions of dollars transferred the two developed medicine companies, Eli Lilly and Novo Nordisk. But the excessive prices of this medicine and the limited insurance coverage made it far for many Americans. Today, this situation began to change with the introduction of ‘lily’ and ‘novo’ low -price buying patients whose coverage of insurance does not include this medicine, at a time when one of the most important intermediaries between insurance companies and pharmaceutical companies reached an agreement with ‘Novo’ which could contribute to reducing the cost of health insurance programs. Parallel, after the availability of the most important medicine to treat obesity, ie “Zepbound” from “Lily” and “Wegovy” from “Novo”, the ban on the sale of low -cost copies via health care companies can be prohibited, forcing patients who depend on these alternatives, to buy original drugs at higher prices. Recent research indicates that “zipond” has shown more effectiveness in weight reduction and reduced fat in the abdominal area. Below are the most prominent developments associated with medication for obesity and the change of methods to obtain it: Weight loss medicines are subject to weight loss medicines for the many changes that have occurred in the level of policy and business. Lily and “Novo” recently started offering medicine at reduced prices for people who pay them directly because they are not included in their insurance coverage. However, the cost is still high as it reaches hundreds of dollars a month for those who pay their own pocket, making it out of the reach of a wide part of the patients. With the improvement of supplies, the governing bodies no longer authorize pharmacies that install medicines by selling forged copies, which were sold at much lower prices than the original medicine. Meanwhile, Novo has recently reduced the price of “Wigofi” medicine in favor of some health insurance plans managed by “Caremark” between the insurance companies and pharmaceutical companies, which are attached to the CVS health. In terms of the agreement, these insurance plans cease to cover the “Zipond” medication of “lily”. But that does not necessarily mean that “wigofi” will become cheaper, although it will be available to more patients, as prices differ according to the details of each insurance plan. On the other hand, patients may be forced to pay higher amounts to obtain ‘zipond’, and they can completely lose the insurance coverage of this medicine unless they get a special release. Some ‘zipond’ users do not like moving to ‘wigofi’, but others prefer to use the usual medicine on it, especially after funded studies from ‘Night’ that surpasses ‘zipond’. The two properties work with two different mechanisms, and they have obtained approvals to treat different cases, along with obesity. Insurance coverage of obesity medication. Many patients cannot obtain insurance coverage or lose it as a result of rejecting a number of insurance companies to cover these expensive medicines, which have forced consumers to pay the costs of their bags or to pay imitating copies available until recently. According to the National Mercer Survey of Health Insurance plans that employers provided for the year 2024, approximately 44% of large businesses cover weight loss medicines, but almost all limit them to the benefit of people who meet strict civil conditions. “Medicir” – the government’s health insurance program for US citizens older than 65 years – does not cover weight loss medicine. The Administration of President Joe Biden obliged ‘Medicir’ to deliver this coverage, but in April the Trump administration rejected this proposal that allowed this medicine to millions of elderly and assigned the government billions of dollars. Weight loss supplies have had trouble meeting Lily and Novo and ‘Novo’ to meet the demand after years of offering their medication. But at the beginning of 2025, the supply crisis was largely resolved, according to the US Food and Drug Administration. The effectiveness of weight loss medicines works both “zibound” and “wigofi” by simulating the appetite GLP-1, which is excreted after eating and giving a sense of saturation. Zipondal is also aimed at another hormone known as GIP, which contributes to reducing blood sugar levels and can increase metabolism. According to a funded study of “Lily”, “Zepopond” helped participants a loss against two additional inches of the waist circumference compared to “Wigofi”, and he achieved an average weight loss of 47% over a 72 week period. The probability of losing at least 25% of weight has doubled in ‘Zepopond’ users compared to users of ‘wigofi’. In addition, the two medicines offer benefits that exceed weight loss. The only “wigofi” is among the GLP-1 medicine that could prevent heart attacks and other cardiovascular problems in obese patients with heart disease. In terms of “zipond”, it became the first remedy in late 2024 to be officially adopted for the treatment of sleep apnea. When is medication for weight loss in the form of tablets? Lily has made promising progress on his experiments with oral medicines to treat obesity, increasing the possibilities to make it easier in the coming years. In April, the company announced that the experimental disc patients helped reduce weight and effectively control blood sugar levels, which is achieved by the ‘Ozempic’ medicine of ‘Novo’ given by injection and user to treat diabetes. And if the results continue with its positive course, ‘Lily’ can present the oral version of the middle in 2026. In addition to the ease of taking the drug in the form of tablets compared to self -information, the cost of manufacturing is also less, which can place this category of medicine within the reach of more people. “Novo” announced on May 2 that the US Food and Drug Administration is now requesting its request to get approval on the oral version of “Wigofi”, which is basically a higher dose of the “rhythus” diabetes tablets. Unlike the competitive medicine of “lily”, this medicine should be taken half an hour before drinking coffee, or breakfast, which can be a hindrance to its wide acceptance. Meanwhile, several companies are still in the early stage of the development of oral medication to treat obesity, while “Pfizer” received a major relapse in this area, which has delayed it a lot about their competitors. This content of “Eastern Economics with Bloomberg”